NIH Gifts Super Bacteria Tech for Custom Immune Cells
Published Date: 7/2/2025
Notice
Summary
The National Institute of Allergy and Infectious Diseases is planning to give CZ Biohub SF, LLC exclusive rights to special technology that helps create immune cells using engineered friendly bacteria. This deal affects researchers and could speed up new treatments for diseases. The agreement will bring focused innovation and may involve funding changes soon.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
NIH Plans Exclusive License to CZ Biohub
The National Institute of Allergy and Infectious Diseases (NIAID) plans to grant CZ Biohub SF, LLC in San Francisco an exclusive inter‑institutional agreement for listed technologies and patent applications that help generate antigen‑specific T and B cells using engineered commensal bacteria. The notice says this deal affects researchers and could speed up new treatments for diseases.
Agreement May Involve Funding Changes Soon
The notice states the inter‑institutional agreement with CZ Biohub SF, LLC may involve funding changes soon. That could affect researchers or institutions tied to this technology.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in